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Background: Clostridium difficile infection (CDI) is the most frequent cause of 
healthcare-associated diarrhoea and is increasingly recognized in the communi-
ty. The epidemiology of CDI in Georgia is unknown.
Methods: Pilot surveillance for CDI among patients with diarrhoea was con-
ducted in four hospital ICUs, and three outpatient clinics in Tbilisi, Georgia. 
Demographic, clinical and treatment data of patients with CDI were collected 
from medical records. A CDI diagnosis was made if the stool sample was posi-
tive for C. difficile toxin A and/or B by nucleic acid amplification test or enzyme 
immunoassay, or by culture of a toxin-producing C. difficile. 
Results: A total of 131 patients with new onset diarrhoeal illness were recruited. 
Of these, laboratory confirmed CDI was found in 24 % (31/131): 32 % (17/53) 
of adult and 20 % (11/55) of paediatric ICU patients, 22 % (2/9) adult and 7 %
(1/14) of paediatric outpatients. Presenting symptoms were fever (>38 °C) and 
diarrhoea with a median duration 7 days. Most CDI cases received antibiotics 
before diagnosis; 94 % of adults and 91 % of children diagnosed in the ICU (me-
dian: 12 days); the majority receiving simultaneously two or more antibiotics. In 
the outpatient settings, 100 % of CDI case-patients received an antibiotic for a 
median duration of 7 days. 
Conclusions: This pilot surveillance demonstrated that C. difficile is a com-
mon cause of diarrhoea in hospitalized and community patients in Georgia. It 
highlights the need to improve the knowledge of medical providers regarding 
the burden of CDI and to establish diagnostic testing at hospital laboratories.
Pilot istra`ivanje Clostridium difficile infekcija u bolesnika s proljevom u
zdravstvenim ustanovama u Tbilisiju, Gruzija
Znanstveni rad
Uvod: Infekcije uzrokovane Clostridium difficile (CDI) naj~e{}i su uzrok pro-
ljeva povezanog sa zdravstvenom skrbi i sve se vi{e prepoznaju u zajednici.
Epidemiologija C. difficile infekcija u Gruziji nije poznata.
Metode: Pilot istra`ivanje C.difficile infekcija kod bolesnika s proljevom pro-
vedeno je u ~etiri bolni~ke jedinice za intenzivno lije~enje (JIL) i tri ambulantne
klinike u Tbilisiju u Gruziji. Podaci o demografskim i klini~kim karakteristika-
ma te lije~enju bolesnika s CDI prikupljeni su iz povijesti bolesti. Dijagnoza C.
difficile infekcije postavljena je ukoliko je uzorak stolice bio pozitivan na C. dif-
ficile toksin A i/ili B testom amplifikacije nukleinskih kiselina ili metodom en-
zimskog imunoeseja ili nalazom C. difficile koji proizvode toksine u kulturi.
Rezultati: U istra`ivanje je bio uklju~en 131 bolesnik s novonastalom dijareal-
nom bolesti. Od toga je laboratorijski dokazana CDI utvr|ena kod 24% (31/131)
bolesnika: u 32 % (17/53) odraslih i 20 % (11/55) djece lije~ene u JIL-u, 22 %
(2/9) odraslih i 7 % (1/14) pedijatrijskih ambulantnih bolesnika. Simptomi su
bili povi{ena tjelesna temperatura (> 38 °C) i proljev s prosje~nim trajanjem od
7 dana. Ve}ina bolesnika s CDI primila je antibiotik prije postavljanja dijag-
noze; 94 % odraslih i 91 % djece lije~ene u JIL-u (medijan: 12 dana); ve}ina je
istodobno primala dva ili vi{e antibiotika. U ambulantnom okru`enju, 100 %
bolesnika s CDI primilo je antibiotik u prosje~nom trajanju od 7 dana.
Zaklju~ak: Ovo pilot istra`ivanje pokazalo je da je C. difficile ~est uzrok pro-
ljeva u hospitaliziranih i izvanbolni~kih pacijenata u Gruziji. Ono nagla{ava
potrebu za pobolj{anjem znanja pru`atelja zdravstvenih usluga vezano uz prob-
leme koje nose infekcije uzrokovane C. difficile te uspostavom dijagnosti~kih
testova u bolni~kim laboratorijima.
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Data collection and analysis
Physicians recruited all patients in ICU with diarrhoea;
all patients (or their family members) who were ap-
proached in the study gave consent. After informed con-
sent, data was collected from medical records using a case
report form. Data abstraction was performed by hospital
physicians trained about CDI and this project. Data includ-
ed patient's age and sex, underlying conditions, admission
date, dates of prior hospitalization, specimen date(s), pro-
cedures, and clinical signs and symptoms of CDI and ex-
posure to antimicrobial therapy, antacids, and chemothera-
py. Data was entered into a database by project epidemiol-
ogists and analyzed using a SPSS 20.0 software package.
Specimen collection and testing
Because microbiological laboratories at the participat-
ing hospitals and clinics were unable to conduct CDI diag-
nostic testing, stool specimens were submitted in clean,
watertight containers to the Richard Lugar Central
Reference Public Health laboratory, Tbilisi, Georgia for
testing. Only liquid stool was accepted. Sample collection
was conducted as soon as possible after onset of symp-
toms. If rapid testing was not feasible, specimens were
stored at 40 °C (for up to 24 hours of collection) or frozen
at –20 °C if the stool could not be processed within 24
hours of collection.
Enzyme-linked immunosorbent assays
In-vitro production of toxins A and B was measured by
enzyme-linked immunosorbent assays (ELISA)
(tgcBIOMICS GmbH) performed on stool specimens.
Because this was one of the first times this type of testing
was performed in Georgia and the incidence of CDI is not
well-recognized, for further confirmation, specimens pos-
itive by ELISA underwent a second step confirmatory
PCR test. Those with positives on both tests were consid-
ered as true positives in the analysis.
Molecular detection of the C. difficile glutamate
dehydrogenase (GDH) and toxin genes
Bacterial DNA was isolated from stool samples using
Fecal DNA Miniprep kit (Zymo Research). Each sample
was tested for the presence of the C. difficile glutamate de-
hydrogenase (GDH) gene (gluD), and toxin genes (tcdA
and tcdB) using polymerase chain reaction (PCR). For de-
tection of gluD, the primers were GluD-s (5'-GTCTTG-
GATGGTTGATGAGTAC-3') and GluD-as (5'-TTCC-
TAATTTAGCAGCAGCTTC-3') [15]. The tcdA gene was
detected using in-house primers Tox-A-s (5'-TGTTG-
GAATAGGTGCTGAAG-3') and Tox-A-ss (5'-AGATG-
GAGATGAGAAAAAGTGA-3') whereas the tcdB gene
was detected using primers NK104 (5'-GTGTAGCAAT-
GAAAGTCCAAGTTTACGC-3') and NK105 (5'-CACT-
TAGCTCTTTGAT TGCTGCACCT-3') [16].
Background
Clostridium difficile is reported to be the most frequent
cause of health care-associated diarrhoea in hospitalized
patients worldwide leading to significant economic costs
on healthcare systems [1 – 10]. Clostridium difficile infec-
tions (CDI) are also increasingly recognized in the com-
munity [11]. In the United States, CDI is responsible annu-
ally for 450,000 infections and is associated with 29,000
deaths [12]. In comparison, the epidemiology of CDI in
Georgia is not well known due to unfamiliarity of the med-
ical staff with this infection and lack of diagnostic tests.
This report describes a pilot surveillance study for CDI in
patients with diarrhoea in several hospitals and outpatient
offices undertaken to elucidate if C. difficile is endemic in
Tbilisi, Georgia.
Methods
From March 1, 2014 through February 29, 2016, a sur-
veillance for CDI among patients with diarrhoea was con-
ducted in four hospital intensive care units (ICU) and three
outpatient clinics in Tbilisi, Georgia. Two adults and two
paediatric hospitals with the largest number of beds in
Georgia and the presence of an ICU were enrolled in the
study. The adult hospitals had 382 and 259 beds, respec-
tively, including 22 and 14 ICU beds. The paediatric hospi-
tals had 319 and 170 beds, respectively, including 32 and
20 ICU beds. The surveillance was limited to patients ad-
mitted to the ICU for ease of recruiting patients and due to
the short length of stay in units outside the ICU. Four out-
patient general medicine and paediatric offices were also
recruited. Patients aged less than 12 months were excluded
due to the high rate of C. difficile colonization during in-
fancy.
The protocol was approved by the hospital research
boards, and signed consents were obtained from patients
or patients' family members.
Definitions
Patients with diarrhoea, defined as at least 3 or more
unformed stools in 24 hours were diagnosed with CDI if
they had a positive laboratory test result for C. difficile tox-
in A and/or B by molecular assay (nucleic acid amplifica-
tion tests, NAAT) or enzyme immunoassay, or by culture
of a toxin-producing C. difficile organism [13 – 14].
Patients were classified as community-associated
(CA-CDI) or healthcare-associated (HA-CDI) depending
on the location of diarrhoea onset and a history of previous
exposure to healthcare. CA-CDI was defined as a patient
with symptom onset in the community, provided that
symptom onset was more than 12 weeks after the last dis-
charge from a healthcare facility [13, 14]. HA-CDI was de-
fined as a patient with symptom onset 48 hours or more af-
ter admission to a healthcare facility.
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Bacteriology and antimicrobial susceptibility
testing
Stool specimens from patients with diarrhoea were
cultured anaerobically using a selective microbial medi-
um, chromlD C. difficile agar (bioMerieux, France) [17].
Pretreatment of stools with ethanol-shock (equal volumes
of ethanol and faeces mixed for 1 hr before inoculation)
was performed to increase the sensitivity of culture [18].
Colonies of C. difficile were selected from culture plates
based on their typical morphology (ground glass appear-
ance) and confirmed as gram-positive rod-shaped bacilli
by Gram staining. 
Isolates were tested for antimicrobial susceptibility
against metronidazole, clindamycin, moxifloxacin and
vancomycin using epsilon test (E-test) strips (bioMerieux,
France). A suspension of C. difficile equivalent to 1
McFarland turbidity standard was swabbed on Brucella
agar plates supplemented with hemin and vitamin K1. An
Etest strip was applied onto the agar surface of each plate
and incubated in an anaerobic atmosphere at 37 °C. The
breakpoints were based on epidemiological cut-off values
recommended by the European Committee on Antimi-
crobial Susceptibility Testing (EUCAST, http://www.eu-
cast.org/). The clinical breakpoints used for metronida-
zole and vancomycin were <_ 2 mg/L for susceptible, and
> 2 mg/L for resistant. An epidemiological cut-off used to
define susceptibility for moxifloxacin was <_ 4 mg/L,
while for clindamycin  <_ 16 mg/L.
Results
Clinical characteristics of CDI patients:
During the 24-month study period, 131 patients with
new onset diarrhoeal disease were recruited (Table 1): 53
at an adult ICU, 55 at a children's ICU; 9 at adult outpa-
tient clinics and 14 at paediatric outpatient clinics. Of the
62 adults, 36 were male (58 %), 26 female (42 %); of the
69 children, 36 were male (52 %) and 33 (48 %) were fe-
male. 
Of the 131 patients, 31 were confirmed as CDI by lab-
oratory testing (see laboratory findings below). Of the 17
adult hospital ICU HA-CDI patients, 6 (35 %) were 60
years or older, the median age was 51 years (range: 26 – 78
years), and the female to male ratio was 0.4. Symptoms of
CDI included: fever with a temperature 38 °C in 16 cases
(94 %), mild-moderate diarrhoea in 14 cases (82 %) (5 –
10 watery stools a day), and severe diarrhoea in three cas-
es (18 %) (>10 watery stools a day). The median duration
of diarrhoea was 7 days (range: 4 – 18 days). None of the
patients received C. difficile specific treatment before
stool specimens were collected, but all were treated with
standard CDI regimens once a diagnosis was made, either
oral metronidazole or vancomycin. All patients were dis-
charged from the hospitals, none required colectomy and
none died.
Of the 11 children hospitalized in the ICU as HA-CDI
patients, 9 (82 %) were two years old and older, the median
age was 2 years (range: 1 – 11 years), and the female to
male ratio was 4.5. Nine patients (82 %) were discharged
from hospitals, two died (18 %), both cases of death were
not related to CDI. Seven patients (64 %) had mild-mod-
erate diarrhoea (5 – 10 watery stools a day), and four pa-
tients (36 %) had severe diarrhoea (>10 watery stools a
day), all patients had fever with a temperature >38 °C. The
median duration of diarrhoea was 7 days (range: 5 – 10
days).
HA-CDI patients were diagnosed 8 – 43 (median: 17)
days after hospital admission and 8 – 35 (median: 12) days
after ICU admission. None had onset of diarrhoea within
48 hrs of admission.
Thirteen (77 %) of the adults and 10 (91 %) of the chil-
dren hospitalized with CDI were intubated. One (6 %)
Surveillance Site Number of patients recruited Laboratory confirmed CDI No. %
Hospital ICU subtotals 108 28 26
Adult Hospital ICUs 53 17 32
Children hospital ICUs 55 11 20
Outpatient office subtotals 23 3 13
Adult outpatient clinic 9 2 22
Paediatric outpatient clinic 14 1 7
Overall Total 131 31 24
Table 1. Percentage of patients with diarrhoea with laboratory diagnosed Clostridium difficile infections, Tbilisi, Georgia, March
2014 – February 2016
Tablica 1. Postotak bolesnika s proljevom i laboratorijski dokazanom infekcijom uzrokovanom Clostridium difficile u Tbilisiju,
Gruzija, u razdoblju od o`ujka 2014. g. do velja~e 2016. g.
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adult and three (27 %) paediatric CDI patients underwent
hemodialysis. 
Admitting diagnoses of adult hospitalized ICU CDI
patients most frequently included brain injury (47 %), low-
er respiratory disease (12 %), trauma (12), sepsis (6 %),
gastrointestinal tract disease (6 %), hysterectomy (6 %),
and cardiovascular disease (6 %). Nine (53 %) adults with
CDI had underlying comorbid conditions: most frequent
were neurological diseases 4 (45 %); one patient (11 %) re-
ported each of the following: diabetes, urinary tract infec-
tion, hepatitis C, epilepsy, and Parkinson's disease. 
Children hospitalized in the ICU with CDI most fre-
quently had diagnoses of lower respiratory tract diseases
(64 %), renal failure (27 %), and cardiovascular diseases
(9 %). Five (46 %) children had an underlying comorbid
illness; these included anorexia, cancer, cerebral palsy,
congenital heart defect and epilepsy. 
All three CA-CDI patients presented to the outpatient
office for evaluation of prolonged diarrhoea (>5 days).
One had an underlying comorbidity: diabetes.
Exposures:
Sixteen (94 %) adults and ten children (91 %) with HA-
CDI received antibiotics prior to their diagnosis with a me-
dian duration of 12 days. Thirteen (76 %) adults and 6
(54 %) of the children received two or more antibiotics si-
multaneously. In outpatient settings, 100 % of CA-CDI re-
ceived an antibiotic for a median duration of 7 days. 
The most common antibiotics received before CDI
among adult HA-CDI patients were ceftriaxone (53 %)
and colistin (47 %). Other antibiotics included meropenem
(30 %), piperacillin/tazobactam (29 %) and vancomycin
(23 %). Similarly, the most common antibiotics pre-CDI in
the paediatric HA-CDI patients were ceftriaxone (45 %)
and colistin (45 %) and carbapenems (meropenem and
imipenem) (39 %). Other antibiotics included cefepime
(27 %) and vancomycin (12 %). Of the three CA-CDI pa-
tients, two received ceftriaxone and one ampicillin/sulbac-
tam, both antibiotics were administered intramuscularly.
PPI was used in 59 % of the adult HA-CD patients and
in 18 % of the children (18 %). Eleven case-patients re-
ceived steroids: six (35 %) adults and five (46 %) children.
No patient was treated with antidepressants. None of the
CA-CDI patients received acid reducers, steroids, or anti-
depressants in the previous 6 months.
Sixty-five percent of HA-CDI patients had a nasogas-
tric feeding tube.
Potential CDI transmission between ICU pa-
tients:
We detected a cluster of three CDI patients at one ICU
suggestive of patient to-patient transmission [19]. The pa-
tients were all diagnosed within a six day period. Two pa-
tients had a high fever (>38 °C), severe diarrhoea (more
than 10 watery stools/day), and severe abdominal pain.
One patient had milder symptoms: a low-grade tempera-
ture, less frequent diarrhoea (5 – 10 watery stools/day),
and minimal abdominal pain. All patients had serious un-
derlying diseases, prolonged hospital stays (>7 days),
cephalosporin exposure and nasogastric feeding. The
transmission of C. difficile was halted by implementing in-
fection control measures (hand hygiene, contact precau-
tions, personal protective equipment, management of fecal
hygiene, disinfection of non-critical patient care equip-
ment, and environmental cleaning). No CDI patients were
diagnosed during the subsequent 6 month follow-up peri-
od.
Laboratory findings
A total of 131 stool samples were collected from pa-
tients with new onset diarrhoea. Of these, 31 samples were
PCR positive for gluD, 30 were positive for both tcdA and
tcdB and one sample was positive for tcdB only. PCR re-
sults of all 31 samples were in full accordance with EIAre-
sults (30 samples were positive for C. difficile toxins A and
B, and one was only positive for toxin B). Of the positive
stool samples, nine (29 %) grew on toxigenic culture. Nine
(100 %) C. difficile isolates were susceptible to van-
comycin, eight (89 %) to moxifloxacin, and five (55 %) to
metronidazole. All C. difficile isolates were resistant to
clindamycin.
Discussion
This is the first report of Clostridium difficile infec-
tions in Georgia. This pilot surveillance in selected Tbilisi
hospitals and outpatient clinics, while having potential
limited generalizability, demonstrated that this infection
was prevalent in selected hospital and community settings,
similar to findings from other countries [20 – 23]. Among
our case patients, the infection appeared to be a more com-
mon cause of diarrhoea in the adult than in the paediatric
population, as 30 % of diarrhoeal stools were positive for
C. difficile in the adult compared to 17 % in the paediatric
population. The diarrhoea was prolonged and in many pa-
tients it was severe (>10 bowel movements per day), but
none of the patients required colectomy and none died.
Diagnosis was often delayed, up to 18 days in one patient,
due to unfamiliarity of the medical staff with this infection.
The high positivity rate (26 %) in adults with diarrhoea in
the ICU, was probably due to recruitment of a high risk
population. 
Similar to other reports, antibiotic exposure was com-
mon; more than 90 % of hospitalized patients (94 % adult
and 91 % children) received antibiotics. It is known that
antibiotics cause disruption of the protective microbiome
in the colon increasing the susceptibility to colonization
and toxin production by C. difficile [26]. This study, like
other studies [23, 25 – 27], showed that third-generation
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cephalosporins were the most common antibiotic used be-
fore CDI; colistin use was also common. A case-control
study will be needed to evaluate the risk of this class of an-
tibiotics for development of CDI. The study also showed
that the simultaneous use of two or more antibiotics was
common and this is known to be associated with an in-
creased risk of CDI [28]. The use of PPI is also common in
adults with HA-CDI, recent meta-analysis has shown that
the use of PPI with antibiotics is associated with an in-
creased risk of CDI in hospitalized patients [29].
Several hospitalized patients received tube feeding and
there was potential transmission between three patients in
one of the ICUs. Acquisition of the organism occurs
through the oral-fecal route; transmission is facilitated by
contamination of the hospital environment and healthcare
workers hands [30]. Reducing the burden of the infection
will therefore require: 1) early identification of patients
and isolation, 2) appropriate hand hygiene by healthcare
workers, 3) environmental cleaning with sporicidal agents
and most importantly 4) reducing unnecessary exposure to
antibiotics.
This pilot study allowed our laboratory to develop and
use various tests such as EIA and PCR for the diagnosis of
CDI and to gain experience in trying to culture the organ-
ism for antimicrobial sensitivity testing. The ability to cul-
ture the organism was less successful than expected and
will need to be further evaluated. Future testing will be
needed to identify the circulating C. difficile strains in
Georgia. In addition, continued education of medical staff
on this disease will be needed to identify those patients
who need treatment and isolation to prevent transmission
in the healthcare setting. We are also planning on educat-
ing the Georgian clinical microbiological laboratories on
methods for the diagnosis of CDI through testing stool by
EIA and PCR. NCDC's Lugar laboratory will continue to
conduct laboratory testing of CDI suspected patients until
testing is implemented by microbiology labs.
Conclusions
While the actual burden of CDI in Georgia has not been
determined, this pilot surveillance study suggests that C.
difficile is a common cause of diarrhoea in hospitalized
and community patients with recent exposure to antibi-
otics in Georgia. Given international experience on its sig-
nificance as a public health problem, it highlights the need
to improve the knowledge of medical providers regarding
the burden of this infection. It also supports the need to im-
plement methods for testing by the clinical microbiology
laboratories. Future surveillance will focus on identifying
the circulating strains beyond Georgia in the Caucasus re-
gion. 
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